Aevi Genomic Medicine Inc. (NASDAQ:GNMX) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), both competing one another are Biotechnology companies. We will contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aevi Genomic Medicine Inc.	N/A	0.00	31.31M	-0.53	0.00
Paratek Pharmaceuticals Inc.	17.12M	10.70	112.36M	-3.64	0.00

Table 1 demonstrates Aevi Genomic Medicine Inc. and Paratek Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides Aevi Genomic Medicine Inc. and Paratek Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aevi Genomic Medicine Inc.	0.00%	-152.1%	-122%
Paratek Pharmaceuticals Inc.	-656.31%	-132.5%	-44.6%

Volatility & Risk

Aevi Genomic Medicine Inc. is 67.00% less volatile than S&P 500 because the company has a beta of 0.33. Paratek Pharmaceuticals Inc.’s 71.00% more volatile than S&P 500 which is a result of the 1.71 beta.

Liquidity

3.1 and 3.1 are the respective Current Ratio and a Quick Ratio of Aevi Genomic Medicine Inc. Its rival Paratek Pharmaceuticals Inc.’s Current and Quick Ratios are 11.4 and 11.4 respectively. Paratek Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Aevi Genomic Medicine Inc.

Analyst Ratings

Ratings and Recommendations for Aevi Genomic Medicine Inc. and Paratek Pharmaceuticals Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Aevi Genomic Medicine Inc.	0	0	0	0.00
Paratek Pharmaceuticals Inc.	0	0	4	3.00

Paratek Pharmaceuticals Inc. on the other hand boasts of a $21.25 consensus price target and a 276.11% potential upside.

Insider & Institutional Ownership

Institutional investors held 19.1% of Aevi Genomic Medicine Inc. shares and 77.7% of Paratek Pharmaceuticals Inc. shares. 0.1% are Aevi Genomic Medicine Inc.’s share held by insiders. On the other hand, insiders held about 3.1% of Paratek Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aevi Genomic Medicine Inc.	-1.04%	2.79%	-80.39%	-83.08%	-88.72%	-70.03%
Paratek Pharmaceuticals Inc.	-6.09%	0.67%	-8.98%	-32.44%	-46.95%	32.36%

For the past year Aevi Genomic Medicine Inc. had bearish trend while Paratek Pharmaceuticals Inc. had bullish trend.

Summary

Paratek Pharmaceuticals Inc. beats on 7 of the 10 factors Aevi Genomic Medicine Inc.

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.